Sun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Aurobindo Pharma has appointed Sanjeev Dani, former senior executive with Ranbaxy Laboratories, as chief operating officer and head of form...

Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.

Sun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.

Most executives from Ranbaxy's earlier team have already left the company in past one year.

Last week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.

After hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce...

The court had earlier issued interim orders to maintain status quo with regard to the merger.

Two individual investors alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.

Shares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...

The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.

Sun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...

Sun Pharma may not have to face surprises emanating from Ranbaxy. There is every likelihood that brand Ranbaxy will see a sunset clause whe...

Undoing of regulatory tangles in Ranbaxy may prove to be challenging for Sun Pharma’s Dilip Shangvi. Here are 5 biggest things Sun needs to...

“This is the biggest deal we have done, but not the most difficult one,” said Sun Pharma chairman Dilip Shanghvi.

Sun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...